KLK3 and prostate carcinoma: In a phase I trial, 12 patients with hormone- and chemotherapy-refractory prostate cancer were treated every 2 weeks for a total of four injections with a DC vaccine targeting prostate stem cell antigen (PSCA) and prostate-specific antigen (PSA) [9].